PACTOL: PAncreatic Disease Cohort of TOuLouse

Sponsor

University Hospital, Toulouse (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05824403

Collaborator

(none)

300

Enrollment

Location

Anticipated Duration (Months)

6.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study is a prospective cohort dedicated to pancreatic diseases excluding cancer. The aim is to develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies. During this study the investigators collect data and biological samples to support research project.

Condition or Disease	Intervention/Treatment	Phase
Pancreatic Diseases

Detailed Description

This collection focuses on pathology of the pancreas requiring specific investigations or management for diagnosis or treatment. Pancreatic pathologies can be classified as malignant, potentially malignant or benign tumors. These can be solid or cystic. There is an inflammatory attack on the pancreas, generating acute pancreatitis in the acute period, if the inflammatory manifestations persist, chronic pancreatitis will develop. Some lesions may be at risk of malignancy during their evolution, it is therefore necessary to improve the performance of monitoring and diagnostic tools in order to adapt the management of patients.

Study Design

Study Type:

Observational

Anticipated Enrollment :

300 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

PAncreatic Disease Cohort of TOuLouse

Anticipated Study Start Date :

May 1, 2023

Anticipated Primary Completion Date :

Mar 1, 2026

Anticipated Study Completion Date :

Mar 1, 2027

Outcome Measures

Primary Outcome Measures

Diagnostic tools [3 years after the first inclusion]
To develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies

Secondary Outcome Measures

New targets [3 years after the first inclusion]
To identify new screening targets
Improvement of management [3 years after the first inclusion]
To improve the management of cystic lesions or Chronic pancreatitis on the decision of therapeutic management
Microbiota [3 years after the first inclusion]
Study of the microbiota of pancreatic diseases
Clinical data access [3 years after the first inclusion]
To make available to the scientific community quality material with associated clinical data also of quality

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Inclusion Criteria:

Patients with inflammatory or cystic exocrine pancreatic pathology
Patient able to read and understand the information leaflet
Patients who have agreed to participate in the study and have signed the free and informed consent
Patients affiliated to a social security system (including AME)